STAT+: Roche ends Huntington’s gene-silencing programs

Article excerpt

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. ARPA-H has unveiled a $160 million effort to speed bespoke gene-editing therapies for rare diseases into the clinic. Meanwhile, Roche has abandoned two Huntington’s gene-silencing drugs after disappointing data, and drugmakers have stepped in to promote Medicare’s new obesity drug discount program. I got coffee with my cousin this morning here in SF. Before leaving for his job at an AI behemoth, he said the bone-chilling July gloom is perfect “working weather.”  Continue to STAT+ to read the full story…